There is not yet a vaccine against the second deadliest infection in the world after tuberculosis: HIV. Rogier Sanders and Godelieve de Bree of the Amsterdam UMC are optimistic about the possibility of developing one now. It’s for the first time that a vaccine is being developed in one hospital (Amsterdam UMC) from the design phase to the safety and efficacy studies in healthy volunteers. It’s also unique that these studies for an HIV vaccine are being done in the Netherlands.
However, actually making the vaccine for testing in humans is very expensive. Rogier and Godelieve are trying to make that happen and are now looking for funding. The potential impact on treating HIV through this vaccine is enormous!
De samenwerking tussen IXA en FEB bij realiseren van Research Centre for Longevity Risk
Iwan Dobbe is bringing the benefits of modern 3D image analysis and printing technology to the clinic. As a researcher at the Biomedical Engineering and Physics department at AMC he devised a method for the design and production of a patient-specific plate for the alignment of bone segments. It requires a single CT scan, preoperative […]
Developing high-quality entrepreneurship education – Amsterdam’s higher education institutions have been working closely together on this since 2008. This was done in the IXAnext valorisation program between 2016 and 2021. We proudly present the main results of the IXAnext program: Ten Amsterdam entrepreneurship cases; Post experience education for alumni; Blended learning modules; A mentoring platform […]